Specialty Pharma, Generics M&A Frenzy To Continue Into 2016: Nomura – ValueWalk Premium
M&A Frenzy

Specialty Pharma, Generics M&A Frenzy To Continue Into 2016: Nomura

The specialty pharmaceutical and generics M&A frenzy that continues to fuel strong sector performance is being driven by a host of factors which could continue to drive M&A activity into 2016, notes Nomura.

Shibani Malhotra and Austin Nelson of Nomura in their September 28, 2015 research note on “Equity: Americas Specialty Pharmaceuticals & Generics” believe sector consolidation will continue as the overall pharmaceutical industry witnesses an increasingly challenging macroeconomic environment.
M&A remains the driver of . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

0